No supporting controlled human study of this exact combination was identified in our September 5, 2026 review. Safety and efficacy together are unestablished. The MOTS-c source studies it independently. It does not demonstrate additional energy, fat loss, fuel utilization or compatibility when combined with the anchor compound.
Why these materials?
Collects receptor pharmacology and the separate literature on the mitochondrial-derived peptide MOTS-c. Tirzepatide is the only metabolic-receptor anchor in this collection. Each material remains a separate product record.
PDL-TZ2: tirzepatide, a GIP and GLP-1 receptor agonist. Equivalence of the catalog material to a regulated medicine is not established.
MOTS-c: AMPK-associated metabolic signaling studied in cellular and mouse models.
PDL-TZ2 is the catalog alias for a synthetic peptide analogue in the dual incretin-receptor research class. Its laboratory record identifies the underlying analyte separately, while the catalog material is supplied as a sealed vial of lyophilized powder for analytical research.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S ribosomal RNA gene. Its name abbreviates mitochondrial open reading frame of the 12S rRNA type-c, and the catalog material is supplied as lyophilized powder in a sealed vial.
Lot documentation published
Stack price$140
One vial of each included product.
Individual value: $155Save $15
Ask about Tirz + MOTS-c
Explore the details with our team.
Contact us for current availability and lot documentation for the products in this selection.
Laboratory research only. Goal labels describe research themes, not promised outcomes or combined-use guidance. Each product is a separate catalog record. Not for human or veterinary use.